Romiplostim for the Emergency Management of Severe Immune Thrombocytopenia with Intracerebral Hemorrhage - Université de La Réunion Access content directly
Journal Articles Frontiers in Neurology Year : 2018

Romiplostim for the Emergency Management of Severe Immune Thrombocytopenia with Intracerebral Hemorrhage

Abstract

Currently, we lack well-established guidelines for the emergency management of severe immune thrombocytopenia (ITP) with life-threatening bleeding. We now report the management of two patients with severe ITP, complicated by substantial cerebral hemorrhage, requiring urgent surgery due to refractory intracranial hypertension. To rapidly boost platelet counts (PCs), corticosteroids, intravenous immunoglobulin, and iterative platelet transfusions were given; all were ineffectual. Romiplostim, a thrombopoietin receptor agonist, was then administered as an "on demand therapy," with the result that a rapid and sustained increase of PCs was achieved, thus allowing for postoperative hemostasis. Both patients recovered good neurological condition, suggesting the potential utility of romiplostim, in combined therapy, for the emergency management of severe ITP.
Fichier principal
Vignette du fichier
fneur-08-00737.pdf (623.97 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Licence : CC BY - Attribution

Dates and versions

hal-04543490 , version 1 (12-04-2024)

Licence

Attribution

Identifiers

Cite

Romain Gellens, Sabrina Habchi, Sebastien Freppel, David Couret, Silvia Iacobelli. Romiplostim for the Emergency Management of Severe Immune Thrombocytopenia with Intracerebral Hemorrhage. Frontiers in Neurology, 2018, 8, ⟨10.3389/fneur.2017.00737⟩. ⟨hal-04543490⟩
0 View
1 Download

Altmetric

Share

Gmail Facebook X LinkedIn More